Phase I/II Study of SY-5007, a RET Inhibitor, in Patients With RET-altered Advanced Solid Tumor
NCT05278364
·
clinicaltrials.gov ↗
PHASE1,PHASE2
Phase
UNKNOWN
Status
184
Enrollment
OTHER
Sponsor class
Conditions
Non-Small Cell Lung Cancer
Medullary Thyroid Cancer
Solid Tumor
Interventions
DRUG:
SY-5007
Sponsor
Shouyao Holdings (Beijing) Co. LTD